Skip to main content

Advertisement

SpringerLink
Log in

Vitamin D receptor agonist supplementation and suppression of inflammation may have advantage for all-cause mortality in hemodialysis patients

  • Original Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

Vitamin D deficiency is common in hemodialysis (HD) patients. The aim of this study was to determine whether HD patients with low 25-hydroxyvitamin D [25(OH)D] levels are at increased risk of mortality.

Methods

This was a prospective cohort study of Japanese HD patients. We selected all patients with measured serum 25(OH)D levels at the time of entry. We assessed the impact of low serum 25(OH)D levels on the long-term mortality of HD patients by performing Cox regression analyses. Associations between serum 25(OH)D levels and all-cause mortality were also investigated.

Results

Data from 100 patients (mean age 61.0 ± 11.8 years, 64 % males) were available. There was a high prevalence (55 %) of 25(OH)D insufficiency < 20 ng/ml, and 51 % of study subjects were treated with alfacalcidol. Twenty-four patients died during a follow-up period of 4.6 years. There were no significant associations between serum 25(OH)D levels and all-cause mortality (p = 0.777). After adjustments for possible confounders, the hazard ratio (with 95 % CI) for all-cause mortality was 1.091 (1.024–1.167) for age, 0.734 (0.566–1.167) for dialysis vintage, 1.012 (0.995–1.031) for serum total cholesterol values, 2.028 (1.093–3.701) for serum phosphate levels, and 0.291 (0.088–0.855) for treatment with alfacalcidol. A survival advantage of alfacalcidol treatment was observed (log-rank, p = 0.0150). The group of subjects whose serum (25(OH)D level was <20 ng/ml and who were not treated with alfacalcidol had the highest mortality rate.

Conclusion

Vitamin D deficiency in HD patients who had not taken vitamin D receptor agonist (VDRA) is associated with an increased risk of all-cause mortality. VDRA supplementation may suppress chronic inflammation and have some advantage for mortality of HD patients with vitamin D deficiency.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Cuppari L, Garcia Lopes MG, Kamimura MA. Vitamin D biology: from the discovery to its significance in chronic kidney disease. J Ren Nutr. 2011;21:113–6.

    Article  PubMed  CAS  Google Scholar 

  2. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.

    Article  PubMed  CAS  Google Scholar 

  3. Bouillon R, Carmelliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008;29:726–76.

    Article  PubMed  CAS  Google Scholar 

  4. Inaguma D, Nagaya H, Hara K, Tatematsu M, Shinjo H, Suzuki S, et al. Relationship between serum 1,25-dihydroxyvitamin D and mortality in patients with pre-dialysis chronic kidney disease. Clin Exp Nephrol. 2008;12:126–31.

    Article  PubMed  CAS  Google Scholar 

  5. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Boitte F, Choukroun G, et al. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1128–35.

    Article  PubMed  CAS  Google Scholar 

  6. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009;75:88–95.

    Article  PubMed  CAS  Google Scholar 

  7. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72:1004–13.

    Article  PubMed  CAS  Google Scholar 

  8. Pecovnik-Balon B, Jakopin E, Bevc S, Knehtl M, Gorenjak M. Vitamin D as a novel nontraditional risk factor for mortality in hemodialysis patients. Ther Apher Dial. 2009;13:268–72.

    Article  PubMed  CAS  Google Scholar 

  9. Mehrotra R, Kermah DA, Salusky IB, Wolf MS, Thadhani RI, Chiu YW, et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int. 2009;76:977–83.

    Article  PubMed  CAS  Google Scholar 

  10. Wang AY, Lam CW, Sanderson JE, Wang M, Chan IH, Lui SF, et al. Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am J Clin Nutr. 2008;87:1631–8.

    PubMed  CAS  Google Scholar 

  11. Chonchol M, Cigolini M, Targher G. Association between 25-hydroxyvitamin D deficiency and cardiovascular disease in type 2 diabetic patients with mild kidney dysfunction. Nephrol Dial Transplant. 2008;23:269–74.

    Article  PubMed  CAS  Google Scholar 

  12. Matias PJ, Ferreira C, Jorge C, Borges M, Aires I, Amaral T, et al. 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrol Dial Transplant. 2009;24:611–8.

    Article  PubMed  CAS  Google Scholar 

  13. Yamshchikov AV, Desai NS, Blumberg HM, Ziegler TR, Tangpricha V. Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials. Endocr Pract. 2009;15:438–49.

    Article  PubMed  Google Scholar 

  14. Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol. 2008;4:404–12.

    Article  PubMed  CAS  Google Scholar 

  15. Tentori F, Albert JM, Young EW, Blayney MJ, Robinson BM, Pisoni RL, et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant. 2009;24:963–72.

    Article  PubMed  CAS  Google Scholar 

  16. Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1529–39.

    Article  PubMed  CAS  Google Scholar 

  17. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:1–201.

    Article  Google Scholar 

  18. Doorenbos CR, van den Born J, Navis G, de Borst MH. Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. Nat Rev Nephrol. 2009;5:691–700.

    Article  PubMed  CAS  Google Scholar 

  19. Sugiura S, Inaguma D, Kitagawa A, Murata M, Kamimura Y, Sendo S, et al. Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events. Clin Exp Nephrol. 2010;14:43–50.

    Article  PubMed  CAS  Google Scholar 

  20. Shoji T, Shinohara K, Kimoto E, Emoto M, Tabata H, Koyama H, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamain D3 users in a hemodialysis population. Nephrol Dial Transplant. 2004;19:179–84.

    Article  PubMed  CAS  Google Scholar 

  21. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, Guinsburg A, Marell C, Rodriguez-Puyol D, et al. Oral active vitamin D is associated with improved survival in hemodialysis. Kidney Int. 2008;74:1070–8.

    Article  PubMed  CAS  Google Scholar 

  22. Ogawa T, Ishida H, Akamatsu M, Matsuda N, Fujiu A, Ito K, et al. Relation of oral 1alpha-hydroxy vitamin D3 to the progression of aortic arch calcification in hemodialysis patients. Heart Vessels. 2010;25:1–6.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a Grant-in-Aid from the Japan Promotion Society for Cardiovascular Diseases.

Conflict of interest

We have no conflict of interest to disclose.

Author information

Authors and Affiliations

  1. Department of Medicine, Medical Center East, Tokyo Women’s Medical University, 2-1-10 Nishiogu, Arakawa-ku, Tokyo, 116-8567, Japan

    Tetsuya Ogawa, Ai Kyono, Masayo Sato, Himiko Sugimoto & Kuniaki Otsuka

  2. Department of Medicine, Kidney Center, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan

    Kosaku Nitta

Authors
  1. Tetsuya Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ai Kyono
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masayo Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Himiko Sugimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kuniaki Otsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kosaku Nitta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kosaku Nitta.

About this article

Cite this article

Ogawa, T., Kyono, A., Sato, M. et al. Vitamin D receptor agonist supplementation and suppression of inflammation may have advantage for all-cause mortality in hemodialysis patients. Clin Exp Nephrol 16, 779–785 (2012). https://doi.org/10.1007/s10157-012-0626-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-012-0626-2

Keywords

Search

Navigation